Adjuvant Pembrolizumab in Patients with Stage IIIA/N2 Non–Small Cell Lung Cancer Completely Resected after Neoadjuvant Concurrent Chemoradiation: A Prospective, Open-Label, Single-Arm, Phase 2 Trial
Cancer Research and Treatment · 2024
DOI: 10.4143/crt.2024.084 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer Research and Treatment, 2024. Verfasst von Junghoon Shin und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Antibodies, Monoclonal, Humanized, Lung Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Merck Sharp & Dohme Corp..
Abstract (Originalsprache)
Purpose
Optimal treatment for stage IIIA/N2 non–small cell lung cancer (NSCLC) is controversial. We aimed to assess the efficacy and safety of adjuvant pembrolizumab for stage IIIA/N2 NSCLC completely resected after neoadjuvant concurrent chemoradiation therapy (CCRT).Materials and Methods In this open-label, single-center, single-arm phase 2 trial, patients with stage IIIA/N2 NSCLC received adjuvant pembrolizumab for up to 2 years after complete resection following neoadjuvant CCRT. The primary endpoint was disease-free survival (DFS). Secondary endpoints included overall survival (OS) and safety. As an exploratory biomarker analysis, we evaluated the proliferative response of blood CD39+PD-1+CD8+ T cells using fold changes in the percentage of proliferating Ki-67+ cells from days 1 to 7 of cycle 1 (Ki-67D7/D1).
Results
Between October 2017 and October 2018, 37 patients were enrolled. Twelve (32%) and three (8%) patients harbored EGFR and ALK alterations, respectively. Of 34 patients with programmed cell death ligand 1 assessment, 21 (62%), nine (26%), and four (12%) had a tumor proportion score of < 1%, 1%-50%, and ≥ 50%, respectively. The median follow-up was 71 months. The median DFS was 22.4 months in the overall population, with a 5-year DFS rate of 29%. The OS rate was 86% at 2 years and 76% at 5 years. Patients with tumor recurrence within 6 months had a significantly lower Ki-67D7/D1 among CD39+PD-1+CD8+ T cells than those without (p=0.036). No new safety signals were identified.
Conclusion
Adjuvant pembrolizumab may offer durable disease control in a subset of stage IIIA/N2 NSCLC patients after neoadjuvant CCRT and surgery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Seoul, Korea.
- Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Korea.
- Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Förderung
- Merck Sharp & Dohme Corp.
Zitieren
APA
Shin, J., Park, S., Kim, K. H., Shin, E. C., Jung, H. A., Cho, J. H., Sun, J. M., Lee, S. H., Choi, Y. S., Ahn, J. S., Kim, J., Park, K., Shim, Y. M., Kim, H. K., Noh, J. M., Ahn, Y. C., Pyo, H., & Ahn, M. J. (2024). Adjuvant Pembrolizumab in Patients with Stage IIIA/N2 Non–Small Cell Lung Cancer Completely Resected after Neoadjuvant Concurrent Chemoradiation: A Prospective, Open-Label, Single-Arm, Phase 2 Trial. Cancer Research and Treatment. https://doi.org/10.4143/crt.2024.084
Vancouver
Shin J, Park S, Kim KH, Shin EC, Jung HA, Cho JH, et al. Adjuvant Pembrolizumab in Patients with Stage IIIA/N2 Non–Small Cell Lung Cancer Completely Resected after Neoadjuvant Concurrent Chemoradiation: A Prospective, Open-Label, Single-Arm, Phase 2 Trial. Cancer Research and Treatment. 2024. doi:10.4143/crt.2024.084
BibTeX
@article{Shin2024,
author = {Shin, Junghoon and Park, Sehhoon and Kim, Kyung Hwan and Shin, Eui-Cheol and Jung, Hyun Ae and Cho, Jong Ho and Sun, Jong-Mu and Lee, Se-Hoon and Choi, Yong Soo and Ahn, Jin Seok and Kim, Jhingook and Park, Keunchil and Shim, Young Mog and Kim, Hong Kwan and Noh, Jae Myoung and Ahn, Yong Chan and Pyo, Hongryull and Ahn, Myung-Ju},
title = {Adjuvant Pembrolizumab in Patients with Stage IIIA/N2 Non–Small Cell Lung Cancer Completely Resected after Neoadjuvant Concurrent Chemoradiation: A Prospective, Open-Label, Single-Arm, Phase 2 Trial},
journal = {Cancer Research and Treatment},
year = {2024},
doi = {10.4143/crt.2024.084}
}
EUVIMED